RDHL
RedHill Biopharma Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-75/100
Last price
0.48
▼ 0.01 (1.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.49
Day high
0.50
Day low
0.48
Volume
57.87K
Market cap
$4.30M
P/E (TTM)
—
52W range
0.47 – 2.14
Trailing performance
Returnvs SPY
1W
+0.62%
-1.3%
1M
-33.15%
-34.3%
3M
-31.83%
-36.4%
6M
-39.50%
-57.7%
YTD
-53.01%
-67.3%
1Y
-74.53%
-90.9%
3Y
-96.20%
-178.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RDHL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+29.06M
Net buying
Buy transactions
2
58.93M shares
Sell transactions
2
29.87M shares
Net transactions
+4
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
0
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 10, 26 | RADAY GILEAD Chief Operating Officer |
CONVERSION | 28.15M | $19.56M | Direct |
| Jul 10, 26 | RADAY GILEAD Chief Operating Officer |
SELL | 14.13M | $9.82M | Direct |
| Apr 6, 26 | RADAY GILEAD Chief Operating Officer |
CONVERSION | 30.78M | $25.52M | Direct |
| Apr 6, 26 | RADAY GILEAD Chief Operating Officer |
SELL | 15.74M | $13.05M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
RADAY GILEAD |
Chief Operating Officer | 218.78M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$4.30M
Enterprise value$-1.62M
Revenue (TTM)$0
Gross profit$0
EBITDA$-7.90M
Net income$-10.87M
EPS (TTM)$0.00
Free cash flow$5.19M
Total cash$5.16M
Total debt$1.07M
Book value / share$0.84
Shares outstanding8.89M
Float4.20M
Short % of float3.93%
Dividend yield0.00%
Beta (5Y)4.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E16.13
PEG ratio—
Price / sales—
Price / book0.58
EV / revenue—
EV / EBITDA0.21
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-22.38%
Debt / equity—
Current ratio0.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $286.00K | $0 | $0 | $61.80M | — | — |
| Operating revenue | $286.00K | $0 | $0 | $61.80M | — | — |
| Cost of revenue | — | $3.19M | $3.46M | $33.34M | $49.41M | — |
| Gross profit | — | $4.85M | $3.07M | $28.46M | $36.35M | — |
| Research & development | $2.02M | $1.59M | $3.53M | $7.28M | — | +27.4% |
| Selling, general & admin | $6.17M | $4.89M | $6.02M | $64.03M | — | +26.3% |
| Total operating expense | $8.20M | $6.47M | $9.55M | $71.31M | — | +26.6% |
| Operating income | -$7.91M | -$6.47M | -$9.55M | -$42.84M | — | -22.1% |
| Net interest income | -$1.33M | -$1.42M | -$1.81M | -$42.21M | — | +6.4% |
| Pre-tax income | -$8.08M | $360.00K | -$18.50M | -$71.67M | — | -2,344.4% |
| Net income | -$429.00K | -$8.27M | $23.92M | -$71.67M | — | +94.8% |
| Net income to common | -$429.00K | -$8.27M | $23.92M | -$71.67M | — | +94.8% |
| Basic EPS | — | — | 100.00 | -1,200.00 | -2,100.00 | — |
| Diluted EPS | — | 0.00 | 100.00 | -1,200.00 | -2,100.00 | — |
| EBIT | -$8.06M | $404.00K | -$18.43M | -$30.34M | — | -2,095.3% |
| EBITDA | -$7.65M | $1.02M | -$16.44M | -$22.18M | — | -848.0% |
| Basic shares | — | 1.29M | 259.12K | 61.63K | 46.53K | — |
| Diluted shares | — | 1.29M | 259.12K | 61.63K | 46.53K | — |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.97M | $4.62M | $5.57M | $19.97M | — | -14.0% |
| Cash & short-term investments | $3.97M | $4.62M | $5.57M | $19.98M | — | -14.0% |
| Accounts receivable | $79.00K | $2.54M | $2.59M | $34.52M | — | -96.9% |
| Inventory | $0 | $3.65M | $4.39M | $11.01M | — | -100.0% |
| Total current assets | $6.53M | $11.91M | $16.14M | $85.90M | — | -45.2% |
| Property, plant & equipment | $1.10M | $437.00K | $1.18M | $7.19M | — | +152.9% |
| Goodwill & intangibles | $5.29M | $5.55M | $5.58M | $65.63M | — | -4.6% |
| Total assets | $25.34M | $18.04M | $23.05M | $158.87M | — | +40.5% |
| Total current liabilities | $19.22M | $22.22M | $19.98M | $197.45M | — | -13.5% |
| Current debt | — | — | — | $115.22M | — | — |
| Long-term debt | — | — | — | — | $83.62M | — |
| Total debt | $1.07M | $356.00K | $1.17M | $122.69M | — | +200.6% |
| Total liabilities | $21.08M | $22.73M | $20.98M | $207.27M | — | -7.3% |
| Retained earnings | -$413.75M | -$414.80M | -$407.74M | -$433.86M | — | +0.3% |
| Shareholder equity | $4.27M | -$4.68M | $2.07M | -$48.40M | — | +191.1% |
| Working capital | -$12.69M | -$10.31M | -$3.84M | -$111.55M | — | -23.1% |
| Net tangible assets | -$1.02M | -$10.23M | -$3.51M | -$114.03M | — | +90.0% |
| Shares issued | 50.92B | 12.99B | 7.87B | 931.96M | — | +292.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$429.00K | -$8.27M | $23.92M | -$71.67M | +94.8% |
| Depreciation & amortisation | $409.00K | $619.00K | $1.99M | $8.15M | -33.9% |
| Stock-based compensation | $457.00K | $665.00K | $1.65M | $5.67M | -31.3% |
| Change in working capital | -$1.97M | $2.05M | -$15.62M | $8.01M | -195.9% |
| Operating cash flow | -$9.65M | -$9.37M | -$35.82M | -$29.18M | -3.0% |
| Capital expenditure | -$5.00K | -$9.00K | -$11.00K | -$198.00K | +44.4% |
| Investing cash flow | $1.69M | -$9.00K | $4.00K | $8.30M | +18,888.9% |
| Financing cash flow | $7.32M | $8.42M | $21.44M | $11.45M | -13.1% |
| Free cash flow | -$9.66M | -$9.38M | -$35.83M | -$29.38M | -3.0% |
| End cash position | $3.97M | $4.62M | $5.57M | $19.97M | -14.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $3.97M | $2.87M | +38.6% |
| Cash & short-term investments | $3.97M | $2.87M | +38.6% |
| Accounts receivable | $79.00K | $5.35M | -98.5% |
| Inventory | $0 | $3.17M | -100.0% |
| Total current assets | $6.53M | — | — |
| Property, plant & equipment | $1.10M | $289.00K | +282.4% |
| Goodwill & intangibles | $5.29M | — | — |
| Total assets | $25.34M | — | — |
| Total current liabilities | $19.22M | $22.29M | -13.8% |
| Total debt | $1.07M | — | — |
| Total liabilities | $21.08M | — | — |
| Retained earnings | -$413.75M | — | — |
| Shareholder equity | $4.27M | — | — |
| Working capital | -$12.69M | — | — |
| Net tangible assets | -$1.02M | -$9.94M | +89.7% |
| Shares issued | 50.92B | — | — |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2022 | 0.00 | 0.00 | 0.0% |
| Sep 2022 | -10.00 | -60.00 | -500.0% |
| Jun 2022 | -10.00 | -20.00 | -100.0% |
| Mar 2022 | -30.00 | -30.00 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions3.55%
Institutions holding15
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.50
-2.95% from price
SMA 20
0.55
-11.78% from price
SMA 50
0.61
-20.81% from price
SMA 100
0.73
-33.79% from price
SMA 200
0.88
-44.72% from price
EMA 12
0.51
-5.78% from price
EMA 26
0.56
-13.46% from price
EMA 50
0.61
-21.12% from price
RSI (14)
36.2
Neutral
MACD (12,26,9)
-0.05
Hist -0.00
ATR (14)
0.03
6.40% of price
Realised vol 30D
120.1%
Annualised
Bollinger upper
0.67
20, 2σ
Bollinger lower
0.42
20, 2σ
50 / 200 cross
Death
0.61 vs 0.88
Trend bias
Below 200
-44.72%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.73
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
120.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-75.9%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.03
6.40% of price
Beta (reported)
4.90
5Y monthly, from filing
Short interest
Shares short
235.26K
Prior 14.71K
Change vs prior
+1,499.9%
Shorts adding
% of float
3.93%
Normal
% of shares out
3.87%
Against total outstanding
Days to cover
0.0
Liquid
Float
4.20M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:25
Split dateAug 20, 2024
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-30
Corporate Changes & Voting Matters
6-K · 2026-09-01
Corporate Changes & Voting Matters
6-K · 2026-08-31
Corporate Changes & Voting Matters
6-K · 2026-08-07
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-28
Offering Registrations
F-3 · 2026-07-02
Corporate Changes & Voting Matters
6-K · 2026-07-01
Headlines
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet
CNW Group · 6d ago
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
PR Newswire · 7d ago
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
Insider Monkey · 27d ago
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
PR Newswire · 36d ago
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
GlobeNewswire · 36d ago
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
GlobeNewswire · 37d ago
Redhill Biopharma Stock Doubles In One Session — Here's Why
Benzinga · 37d ago
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
CNW Group · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.